Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 17, 2021

Primary Completion Date

March 15, 2026

Study Completion Date

March 15, 2026

Conditions

Hematopoietic and Lymphoid Cell NeoplasmSteroid Refractory Graft Versus Host Disease

Interventions

OTHER

Cellular Therapy

Given ds-MSCs IV

DRUG

Ruxolitinib

Given PO

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER